Canadian Budget Does Not Go Far Enough
CGPA Welcomes Investment But Calls For A More Comprehensive Strategy
While a promised investment in the life sciences sector included in the latest Canadian federal budget has been welcomed by the local off-patent industry, it says a “more comprehensive approach” is needed.
You may also be interested in...
In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.
Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.
Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.